As of 2025-07-07, the Intrinsic Value of Kilitch Drugs (India) Ltd (KILITCH.NS) is 300.68 INR. This KILITCH.NS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 430.45 INR, the upside of Kilitch Drugs (India) Ltd is -30.10%.
The range of the Intrinsic Value is 243.19 - 389.93 INR
Based on its market price of 430.45 INR and our intrinsic valuation, Kilitch Drugs (India) Ltd (KILITCH.NS) is overvalued by 30.10%.
Range | Selected | Upside | |
a | |||
DCF (Growth 5y) | 243.19 - 389.93 | 300.68 | -30.1% |
DCF (Growth 10y) | 691.28 - 1,121.78 | 860.22 | 99.8% |
DCF (EBITDA 5y) | 667.70 - 1,516.28 | 939.20 | 118.2% |
DCF (EBITDA 10y) | 1,095.61 - 2,465.63 | 1,534.95 | 256.6% |
Fair Value | 409.17 - 409.17 | 409.17 | -4.94% |
P/E | 254.67 - 429.58 | 340.10 | -21.0% |
EV/EBITDA | 137.71 - 347.40 | 229.92 | -46.6% |
EPV | 3.96 - 10.05 | 7.01 | -98.4% |
DDM - Stable | 80.73 - 159.07 | 119.90 | -72.1% |
DDM - Multi | 391.81 - 616.40 | 480.48 | 11.6% |
Market Cap (mil) | 6,921.64 |
Beta | 1.13 |
Outstanding shares (mil) | 16.08 |
Enterprise Value (mil) | 7,317.87 |
Market risk premium | 8.31% |
Cost of Equity | 15.73% |
Cost of Debt | 10.36% |
WACC | 15.36% |